EyePoint names Michael Campbell as chief commercial officer
EyePoint Pharmaceuticals appointed Michael Campbell as Chief Commercial Officer to lead commercial strategy and launch preparedness for DURAVYU (vorolanib intravitreal insert), currently in Phase 3 development for wet age-related macular degeneration and diabetic macular edema. Campbell will oversee commercial planning ahead of pivotal data readouts expected mid-2026 and potential U.S. market entry pending regulatory approval.
Why it mattersDURAVYU's Phase 3 program for wet AMD and DME makes Michael Campbell critical for payer access.